Cancer Stem Cell Therapies in Gastrointestinal Cancers

Slides:

Advertisements

Similar presentations

The Nurse View: Management of Pancreatic Cancer

Advertisements

Perspectives on Managing Polycythemia Vera for the Nurse Practitioner and Physician Assistant.

Endocrine Combinations in HR-Positive MBC: The Future Is Now

Introduction. TREATMENT BASED ON TUMOR SIDEDNESS IN mCRC: THE EVIDENCE AND PRACTICAL APPLICATION.

Introduction/Background

An Introduction to DNA Damage Repair in Cancer: Beyond PARP

Program Goals. Clinical Considerations in the Use of Checkpoint Inhibitors for Gastrointestinal Cancers.

Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

What to Do Next: Sequencing of Therapy in Patients With Metastatic CRC

Effective Management of Psoriatic Arthritis: Tailoring Treatments

BRCA, HRR Deficiency, and PARP Inhibitors

Introducing JAK Inhibitors in Rheumatoid Arthritis

Dry AMD and GA: The Present and Future

Discussion Outline Cells of the Immune System.

At The Cutting Edge of Developments in the Management of Hyperkalemia

Current Controversies in Multiple Sclerosis Management

Overall Program Goals. Overall Program Goals Current Approaches.

Part 1: Disease Activity Measures

RAI-Refractory Thyroid Cancer: Optimizing Treatment With Multikinase Inhibitors.

Metastatic Renal Cell Carcinoma

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Program Goals. Targeting New Pathways for Overcoming Endocrine Resistance in Breast Cancer.

American Heart Association Scientific Sessions

Clinical Presentations of VTEa,b NOACs VTE Acute Treatment Trials.

Activity Goals. Perspectives on PARP Inhibitors in Ovarian Cancer Has the Time Come for Individualized Care?

SGLT2 Inhibitors in the Modern Era: Why and Where?

Activity Goals. Activity Goals Discussion Topics.

Program Goals. The Clinical Impact of Second-Generation Antihormonal Therapy in the Treatment of mCRPC.

Bone-Targeted Therapy in the Adjuvant Breast Cancer Setting

How Effective Is Fixed-Dose Combination Therapy in T2D and Where Does It Fit?

CDK4/6 Inhibitors in Breast Cancer:

Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma

PAH Therapy Revisited.

Novel Therapies for the Treatment of MS

Managing gBRCA-Positive Metastatic Breast Cancer

Individualizing Care in Ovarian Cancer

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: First-line Considerations.

EHL Technologies in Hemophilia Care

A Spotlight on PI3K Inhibition in Relapsed/Refractory B-Cell Lymphoma

Program Goals. Implementing the Updated American Thyroid Association Guidelines and Recommendations for RAI-R DTC.

Program Goals Overview Glatiramer Acetate 3 Times a Week.

Immunotherapy for cSCC

The JAK-STAT Pathway and Graft-vs-Host Disease

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

Program Goals Basal Cell Cancer Basal Cell Cancer: Beyond Surgery.

Advancing Care Across the Spectrum of Pancreatic Cancer

Case #1 Case #1 (cont) Case #1 (cont)

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Advances in Rheumatoid Arthritis Management

Getting to Grips With the Science of CGRP and Migraine

What's New in Therapeutic Options for Moderate to Severe RA?

The Road to Quality Improvement in HER2-Positive Breast Cancer

Advancing Patient Care in RA

CMV in the HSCT Recipient

Battling the Flu: Latest Advances in the Influenza Treatment Arsenal

Treatment of Locally Advanced Pancreatic Cancer

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Managing Patients with Relapsed CLL who Discontinue BCR Signaling Inhibitors.

Severe Asthma and Comorbidities

New Paradigms in HR-Positive Advanced Breast Cancer

Update on the Management of Atopic Dermatitis

Incorporating Prostacyclins Into Practice

Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.

Prostacyclin Pathway Agents in Action

Timothy R. Donahue, David W. Dawson Cell Stem Cell

Targeting Apoptosis in AML

Targeting IL-23 for Therapeutic Longevity in Psoriasis

PAH Pathways: What Do the Data Tell Us?”

Anemia Explored.

Presentation transcript:

Cancer Stem Cell Therapies in Gastrointestinal Cancers

Cancer Stem Cells

Cancer Stemness

CSC Signaling Pathways

CSC Treatment Targets

Stemness Mechanisms of Progression/Relapse

Targeted Pathway Example: STAT3

Demcizumab in Pancreatic Cancer

Demcizumab Phase 1B Results

Demcizumab Phase 1B Safety Findings

ɣ-Secretase Inhibitor in Pancreatic Cancer

Napabucasin in Pancreatic Cancer

Napabucasin 1b/2 Study Results and Safety

Napabucasin Registrational Study

Napabucasin in mCRC: Methods and Safety

Napabucasin in mCRC: Results

CCTG/AGITG CO.23 Trial

CanStem303C Trial

Clinical Impact and Future Directions

Abbreviations

Abbreviations (cont)